Type I interferon (IFN-I) signaling paradoxically impairs host immune responses during many primary and secondary bacterial infections. Lack of IFN-I receptor reduces bacterial replication and/or bacterial persistence during infection with several bacteria. However, the mechanisms that mediate the adverse IFN-I effect are incompletely understood. Here, we show that Usp18, an interferon-stimulated gene that negatively regulates IFN-I signaling, is primarily responsible for the deleterious effect of IFN-I signaling during infection of mice with Listeria monocytogenes or Staphylococcus aureus. Mechanistically, USP18 promoted bacterial replication by inhibiting antibacterial tumor necrosis factor- (TNF-) signaling. Deleting IFNAR1 or USP18 in CD11c-Cre + cells similarly reduced bacterial titers in multiple organs and enhanced survival. Our results demonstrate that inhibiting USP18 function can promote control of primary and secondary bacterial infection by enhancing the antibacterial effect of TNF-, which correlates with induction of reactive oxygen species (ROS). These findings suggest that USP18 could be targeted therapeutically in patients to ameliorate disease caused by serious bacterial infections.
INTRODUCTION
Primary and secondary bacterial infections are major public health concerns across the globe given their prevalence and accelerated development of widespread resistance to antibiotic therapies. Modulating host responses has the distinct advantage of exerting less selective pressure on bacterial populations and potentially being broadly effective against multiple bacterial species. Type I interferon (IFN-I) signaling has been reported to both contribute to protection and increase susceptibility to bacterial infections (1) (2) (3) . Moreover, elevated IFN-I production after viral infection has been causally linked with promoting host susceptibility to secondary bacterial infections (4) (5) (6) (7) (8) (9) , some of which can result in severe morbidity and mortality. Despite a causal link between IFN-I signaling and susceptibility to bacterial infection, the cellular and molecular mechanisms by which IFN-I signaling promotes primary and secondary bacterial infection are not well defined.
The IFN-I family contains multiple members, mainly divided into two groups (IFN-s and IFN-) (10) . All members share the same receptor IFNAR, which consists of two subunits, IFNAR1 and IFNAR2. Signaling through IFNAR leads to the phosphorylation of two receptor-associated kinases: tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1). These kinases recruit signal transducer and activator of transcription 1 (STAT1) and STAT2 that form either homo-or heterodimers and translocate to the nucleus to originate the transcription of IFN-I-stimulated genes (ISGs) (11) . One of the most highly induced ISGs is ubiquitin-specific protease 18 [USP18 or UBP43 (ubiquitin binding protein 43) ] (12) . USP18 itself inhibits IFNAR signaling in a negative feedback loop by binding to IFNAR2 and displacing JAK1 (13) . Recently, it was also demonstrated that USP18 can directly interact with STAT2 to form a complex that inhibits IFN-I ligand binding to IFNAR2 (14, 15) . USP18 has an additional functional domain that exerts isopeptidase activity and removes the ubiquitin-like modifier ISG15 from conjugated proteins (12) . A mutation of USP18 within the Cys box at position 61 in mice [Usp18 C61/C61 transgenic mice (16, 17) ] or at position 64 in humans abolishes the isopeptidase activity of the protein, whereas a mutation at site 361 in mice [Usp18 ity9 mice (18) ] or at site 365 in human abolishes both the IFNAR antagonistic and isopeptidase functions of Usp18 (table S1). Although both mutations have been extensively demonstrated to contribute to promoting virus infection (16, 17) , the role of Usp18 in bacterial infection has not been rigorously studied. Using a mutant Usp18 mouse model, Usp18 ity9 , two groups demonstrated that mutant animals were more susceptible to Salmonella typhimurium and Mycobacterium tuberculosis than wild-type (WT) controls (17, 18) . However, in a separate study, it was demonstrated that knockout mice lacking Usp18 exhibited enhanced control of S. typhimurium compared with Usp18-sufficient controls (19) . The discrepancy between the above studies suggests that specific domains in the USP18 protein may differentially regulate bacterial infection.
Despite the crucial role of IFN-I during bacterial infection, studies to date have only reported on the consequences of the absence of IFN-I in bacterial control (3) . Moreover, given the ability of IFN-I to induce hundreds of ISGs, whether a single specific ISG contributes to the negative effect of IFN-I has yet to be reported in either bacterial or viral infection (20) . In this study, we wanted to further explore how IFN-I mechanistically increases the susceptibility to both primary and secondary bacterial infection with a focus on the role of specific ISGs.
RESULTS

Usp18 is an important IFN-I-induced gene that promotes L.m. infection
We set out to determine the cellular subsets that require IFN-I signaling and define whether specific ISGs promote bacterial infection. To answer these questions, we used a mouse model of Listeria monocytogenes (L.m.) infection, which has been previously reported to require IFN-I signaling for optimal L.m. replication and dissemination (4-9). L.m. has been described to enter both macrophages and dendritic cells (DCs) early after infection, and these cell types are important for L.m. infection and distribution (21) (22) (23) . By assessing ISGs, we found that DCs are more responsive to IFN-I than macrophages after L.m. infection with elevated expression levels of various ISGs (Fig. 1A and fig. S1 ). The up-regulation of these ISGs required IFNAR signaling because blocking IFNAR1 with a neutralizing antibody reduced their expression to levels similar to uninfected mice (Fig. 1A and fig. S1 ). L.m. infection of mice that lack the IFN-I receptor mainly on DCs (Ifnar fl/fl CD11c-Cre) resulted in significantly reduced bacterial titers in liver and spleen and reduced titers in kidney and lung 4 days after infection (Fig. 1B) . In contrast to DCs, infection of Ifnar fl/fl LysM-Cre mice that lack IFNAR1 receptor on macrophages and monocytes resulted in similar bacterial titers in liver, spleen, lung, and kidney as Cre-negative littermate controls ( fig. S2 ). Together, our results demonstrate that IFN-I signaling in CD11c + DCs, rather than macrophages, is crucial to amplify L.m. infection.
Given the requirement of IFN-I signaling in CD11c + DCs to promote L.m. infection, we sought to identify whether a specific ISG downstream of IFN-I signaling in DCs might explain this phenomenon. Upon analysis of the ISGs up-regulated during L.m. infection, ubiquitin-specific peptidase 18 (Usp18) was elevated in both DCs and macrophages (Fig. 1A) . This finding was unexpected because we found here, and in our previous work (24) , that Usp18 transcripts were higher in DCs compared with macrophages from uninfected animals (Fig. 1C) , although Usp18 was induced in both cell types after infection with L.m. (Fig. 1A and fig. S3 ). Thus, we hypothesized that USP18 itself may play a negative role downstream of IFN-I signaling during L.m. infection. To directly assess the role of USP18 during L.m. infection, we infected Usp18-deficient mice with L.m. and analyzed bacterial titers after 4 days. We found that Usp18 −/− mice were more resistant to L.m. infection, demonstrated by significantly reduced bacterial titers in multiple organs (Fig. 1D ). This finding was particularly unexpected because all other ISGs measured were significantly more elevated in Usp18-deficient mice due to lack of its inhibitory effect on IFN-I signaling ( fig. S4 ). Our data strongly suggest that Usp18 is an important ISG capable of promoting L.m. infection. (Fig. 2B) . In contrast, lack of Usp18 in LysM-Cre + cells increased rather than reduced L.m. titers (Fig. 2C) , suggesting that Usp18 is a major ISG in CD11c-Cre + cells, which acts to promote L.m. infection. Consistent with this finding, blocking IFN-I signaling in control mice reduced L.m. to the same level as in Usp18 fl/fl CD11c-Cre mice treated with isotype control antibody (Fig. 2D) . However, blocking IFN-I in Usp18 fl/fl CD11c-Cre mice reduced L.m. titers only in liver but not in other examined tissues (Fig. 2D) (Fig. 2F) . Moreover, deletion of Usp18 specifically in CD11c-Cre + cells resulted in significant reductions in bacterial titers compared with littermate controls (Fig. 2G) .
Deletion of
Together, our data demonstrate that the probacterial USP18 effect is observed with an additional IFN-I-sensitive Gram-positive bacterial species and suggest that inhibition of USP18 may help to control other IFN-sensitive bacterial infections.
Probacterial effect of USP18 is independent of its isopeptidase activity or an effect on cytokine production We investigated the mechanism by which Usp18 expression in DCs promotes L.m. infection. As mentioned above, USP18 has two well-described activities: One enables binding to the intracellular domain of the IFNAR2 subunit and attenuates JAK-STAT signaling downstream of IFN-I binding, and the other exerts isopeptidase function and removes ISG15 from conjugated proteins (12) . To analyze the contribution of the protease activity of USP18, we infected WT and Usp18 C61A/C61A knock-in mice (16) , which express only a catalyt ically inactive USP18 protein, with L.m. and bacterial titers were measured. Usp18 C61A/C61A mice showed similar or even elevated bacterial titers compared with WT controls, which suggests that the USP18 effect on L.m. infection is independent of log-rank (Mantel-Cox) test (B). n.s., not significant; *P < 0.05; **P < 0.01. Data are pooled from two independent experiments (A to C, F, and G).
its isopeptidase activity (Fig. 3A) . To further exclude the role of ISGylation/deISGylation in mediating the function of USP18, we used Ube1L −/− mice that lack the ability to conjugate ISG15 to its substrates (28) . Ube1L −/− mice exhibited similar bacterial titers in the investigated organs (Fig. 3B ). This suggests that neither ISGylation nor deISGylation is important to control L.m. infection. Given that USP18 displays a strong ability to negatively regulate IFN-I signaling (12, 29) , we reasoned that the absence of Usp18 expression may promote cytokine production, particularly elevation of early IFN- and tumor necrosis factor- (TNF-), cytokines known to promote control of L.m. infection (30, 31) . However, the levels of antibacterial cytokines (IFN- and TNF-) were reduced in knockout mice compared with littermate controls (Fig. 3C) , suggesting that the IFN-I antagonistic effect of USP18 is likely not at play in controlling L.m. infection.
USP18 inhibits the antibacterial effect of TNF-
Previous studies showed that silencing USP18 can enhance TNF- signaling (32) . The USP18 effect was demonstrated to be executed by its interaction with TAK1 and NEMO (21) (fig. S9A ), two proteins involved in TNF-induced nuclear factor B (NF-B) signaling. Human USP18 variants with point mutations in the IFNAR2 binding domain L365F or isopeptidase domain C64A (12) were still able to interact with TAK1 and NEMO ( fig. S9A ). In addition, overexpression of human USP18 in HeLa cells reduced NF-B phosphorylation after TNF- treatment ( fig. S9B ). Moreover, overexpression of USP18 L365F or USP18 C64A in HeLa cells still resulted in inhibition of NF-B phosphorylation after TNF- treatment ( fig. S9B ), which strongly suggests that these domains are not essential for regulating TNF- signaling. To check whether DCs that lack USP18 exhibit increased TNF- signaling, we treated bone marrow-derived DCs generated from Usp18 fl/fl CD11c-Cre and littermate control mice with TNF-. We noticed elevated phosphorylation levels of NF-B p65 in Usp18-deficient DCs ( fig. S9C ). Our results suggest that USP18 attenuates TNF- signaling through an unknown mechanism that is independent of the IFNAR2 binding and isopeptidase domains.
We next asked whether the antibacterial effect of TNF- is enhanced in Usp18-deficient DCs. Treatment of bone marrowderived DCs generated from Usp18 fl/fl CD11c-Cre mice with TNF- showed higher levels of iNOS expression than WT DCs (Fig. 4A ). In addition, the generation of reactive oxygen species (ROS) was enhanced in Usp18-deficient DCs after TNF- treatment both in vitro and in vivo (Fig. 4B and fig. S10 ). Moreover, we observed a significant increase in the generation of ROS in DCs of Usp18 fl/fl CD11c-Cre mice in comparison with littermate controls after L.m. infection (Fig. 4C) . To assess whether enhanced TNF- signaling in Usp18-deficient DCs translated to better bacterial control, we infected DCs in vitro with L.m. in the presence or absence of TNF-. Usp18-deficient DCs showed stronger efficiency in killing bacteria after TNF- treatment than WT DCs, with ~2-log reductions in bacterial titers in Usp18-deficient compared with WT DCs (Fig. 4D) . To further confirm our finding, we treated THP-1 monocytes that overexpressed USP18 or control THP-1 monocytes with TNF- and infected them with L.m. USP18 overexpression significantly blunted the antibacterial effect of TNF- (Fig. 4E) . Next, we treated CD11c-Cre mice to similar levels as littermate controls (Fig. 4F and   fig. S11A ). Moreover, treatment of mice with 10-fold less anti-TNF- antibody still inhibited bacterial control in Usp18 fl/fl CD11c-Cre animals ( fig. S11B) . We hypothesized that USP18 may also prevent the phosphorylation of JAK1 after IFN-R signaling, similarly to how USP18 inhibits IFNAR2 signaling. However, Usp18 fl/fl CD11c-Cre mice still exhibited enhanced control of L.m. infection in multiple organs even after blocking IFN- compared with Usp18 fl/fl control mice (Fig. 4G and fig. S11C ), which strongly suggests that USP18 does not inhibit the antibacterial effect of IFN- and that the enhanced ability of Usp18-deficient DCs to control L.m. is highly dependent on intact TNF- signaling.
The probacterial role of IFN-I during superinfection is USP18-dependent Elevated IFN-I production after viral infection has been causally linked with promoting host susceptibility to secondary bacterial infections (2, 3) . Given the requirement of IFNAR1 signaling in DCs to promote primary L.m. infection, we asked whether IFNAR1, specifically on CD11c + DCs, could promote bacterial superinfection. To address this question, we infected Ifnar fl/fl CD11c-Cre or Cre-negative littermates with acute lymphocytic choriomeningitis virus (LCMV), which induces high levels of IFN-I within 24 to 48 hours (33) . After 2 days, mice were superinfected with L.m., and bacterial titers were measured 4 days after L.m. infection. In agreement with a previous report (5), L.m. superinfection after primary LCMV infection resulted in significantly elevated L.m. titers in liver, spleen, kidney, and lung in littermate control mice (Fig. 5A) . The absence of IFNAR1 expression in DCs was sufficient to reduce L.m. titers to similar levels as detected in Ifnar fl/fl CD11c-Cre mice infected with L.m. alone (Fig. 5A ). This result strongly suggests that LCMV-derived IFN-I exerts a DCintrinsic negative role during viral-bacterial superinfection. Next, we asked whether Usp18 deficiency in DCs would also promote control of L.m. after superinfection with LCMV. Usp18 fl/fl CD11c-Cre mice were more resistant to L.m. infection as compared with littermate controls with lower bacterial titers in liver, spleen, kidney, and lung (Fig. 5B) . Despite stronger IFN-I signaling in DCs from Usp18 fl/fl CD11c-Cre mice ( fig. S12 ), bacterial titers in LCMV-L.m. superinfected Usp18 fl/fl CD11c-Cre mice were even lower than observed in single infected littermate control mice (Fig. 5B) . Moreover, L.m. titers in spleen, kidney, and lung were comparable in primary and secondary infected Usp18 fl/fl CD11c-Cre mice. Analogous to viral infection, induction of IFN-I production by treating mice with polyinosinic:polycytidylic acid (poly I:C) at the same time as L.m. infection increased bacterial titers in control mice (Fig. 5C ). Titers were similar in spleen, kidney, and lung of Usp18 fl/fl CD11c-Cre mice whether they received poly I:C or control injections (Fig. 5C ). Although bacterial titers were increased in liver of poly I:C-treated Usp18 fl/fl CD11c-Cre mice, titers remained lower than untreated littermate controls and were significantly reduced compared with poly I:C-treated littermate controls (Fig. 5C) .
DISCUSSION
In summary, we define Usp18 as an essential ISG downstream of IFN-I signaling that promotes susceptibility to both primary and secondary bacterial infection through attenuating antibacterial TNF- signaling and subsequent ROS production. Further, we demonstrate that USP18 attenuation of TNF- signaling does not require either the deISGylation or IFN-I antagonistic functions of USP18 and most likely occurs via an unidentified domain on USP18. Our results are unexpected given that the absence of USP18 augments IFN-I signaling (29, 34) and is associated with prolonged JAK-STAT signaling, which, if the current paradigm is correct, should promote rather than prevent L.m. infection. Moreover, because IFN-I signaling has been reported to promote bacterial infection by multiple pathogens, including M. tuberculosis, Francisella tularensis, S. typhimurium, and S. aureus (3), therapeutically targeting USP18 could be applicable and transformative for treatment of these diseases without attenuating IFN-I signaling, which could be detrimental to control endogenous and acquired viral infections. We support this notion by demonstrating that the probacterial effect of USP18 is involved during infection with Gram-positive bacteria: Usp18 deficiency in DCs resulted in reduced bacterial titers after S. aureus infection (Fig. 2G) . Moreover, IFN-I signaling has been reported to be protective during many bacterial infections, such as Helicobacter pylori, Streptococcus pyogenes, or Legionella pneumophilla (3) . Given that Usp18 deficiency results in increased IFN-I signaling, it would be interesting to test how Usp18 deletion or inhibition affects these bacterial infections. However, it is noteworthy to mention that Usp18 expression may be required in different cell subsets to exert probacterial effects, which will likely depend on the bacterial species being studied, and this should be considered when testing additional bacterial infections.
To study the role of IFN-I on DCs during L.m. infection, we used Ifnar fl/fl CD11c-Cre and Usp18 fl/fl CD11c-Cre mouse models. Although CD11c is expressed on multiple cell types including activated T cells (35) , we believe that effects on bacterial infection in our models using CD11c-Cre mainly result from DC deletion due to our focus on early times after infection. Moreover, we exclude the role of other innate cells (neutrophils, monocytes, and macrophages) by using LysM-Cre mice that displayed similar L.m. titers as Cre-negative littermate controls. In addition to understanding the specific cell types that require USP18 to mediate its probacterial effects, whether USP18 can be targeted pharmacologically has not been addressed to date. Thus, it is unclear whether USP18 could be inhibited therapeutically to control primary and secondary bacterial infections without promoting overt pathology due to its IFN-I IFN- and TNF- production were measured in the serum at the indicated time points (n = 4 to 6). Statistical significance was determined by Student's t test (A and B) and two-way ANOVA (C). n.s., not significant; *P < 0.05; **P < 0.01. Data are pooled from two independent experiments (A to C).
antagonistic functions. In humans, mutations that result in USP18 deletion lead to interferonopathy, severe pathological manifestations, and premature death (36) . This suggests that targeting USP18 could provoke life-threatening consequences. However, congenital deletion of USP18 at birth may not mimic pharmacological inhibition. This is emphasized by the identification of patients who lack ISG15 and who also have significantly reduced expression of USP18 due to the ability of ISG15 to stabilize USP18 protein expression (37) . It is noteworthy to mention that these patients live to adulthood and their cells are less susceptible for viral infection (38) . These studies suggest that USP18 can be inhibited without causing life-threatening pathological manifestations. An additional open question is how USP18 regulates TNF- signaling in innate immune cells. A previous study demonstrated that USP18 can bind to and regulate proteins downstream of TNF- signaling (32) . Moreover, USP18 has been shown to act both alone and After 4 days, titers of bacteria were measured in the indicated organs (n = 4 to 5). Data are representative of at least two independent experiments. Statistical significance was determined by Student's t test (A to G). n.s., not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Data are pooled from two independent experiments (B and E). with or without 200 g of poly I:C. Bacterial titers were measured in the indicated organs on day 3 (n = 4 to 6). Statistical significance was determined by Student's t test (A to C). n.s., not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Data are pooled from two independent experiments.
in combination with other molecules. For instance, in addition to STAT2-USP18 complex, it has been demonstrated that USP18 can recruit an additional ubiquitin-specific peptidase, USP20, to deubiquinate STING independently of the enzymatic domain of USP18 (39) . Therefore, it is possible that USP18 may also regulate TNF- signaling by recruiting other USP proteins. These findings highlight the importance of studying whether USP18 has additional functional domain(s) and whether USP18 can inhibit TNF- signaling by itself or in combination with other protein(s). Collectively, our results suggest that inhibition of USP18 function could be extended to other medically important bacterial infections that are IFN-I-sensitive. Our data, coupled to the known proviral role of USP18 (16, 33, 40, 41) , suggest that this protein could be pharmacologically targeted to help control both viral and bacterial infections. Moreover, targeting host USP18 will have the distinct advantage of exerting less selective pressure on viral or bacterial populations and thereby will likely attenuate the development of antibiotic resistance.
MATERIALS AND METHODS
Study design
In this study, we aimed to determine the mechanism by which IFN-I signaling can influence bacterial infection. To do that, we used different transgenic mice and two strains of bacteria, L.m. and S. aureus. First, we determined which cell types are more responsive to IFN-I during L.m. infection by using conditional knockout mice of IFNAR (Ifnar fl/fl CD11c-Cre and Ifnar fl/fl LysM-Cre). We hypothesized that one ISG (USP18) in DCs is responsible dominantly in increasing susceptibility to L.m. To check that, we also used conditional knockout mice of Usp18 (Usp18 fl/fl CD11c-Cre, Usp18
fl/fl LysM-Cre). We confirmed our finding by treating Usp18-deficient mice with IFNAR blocking antibody before infection. To determine which functional domain of USP18 is responsible for its probacterial role, we infected knock-in mice that have a mutation in the isopeptidase domain of Usp18 (Usp18 C61A/C61A
) and Ube1L −/− mice. These strains have normal IFN-I signaling but lack the ability of deISGylation or ISGylation, respectively. We also investigated the ability of USP18 to inhibit antibacterial signaling of TNF-. We measured ROS after TNF- treatment in vitro and in vivo in Usp18-deficient DCs. In addition, we analyzed the ability of USP18 to inhibit bactericidal effect of TNF-. Finally, we investigated the role of USP18 during secondary bacterial infection by using viral infection (LCMV) or during induction of IFN-I with a synthetic double-stranded RNA (poly I:C). Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany) and were maintained in heart infusion agar. S. aureus (strain 27217) were purchased from ATCC and maintained in heart infusion agar. LCMV strain WE was originally obtained from F. Lehmann-Grube (Heinrich Pette Institute, Hamburg, Germany) and propagated in L929 cells. For all experiments, both LCMV-WE and L.m. were injected by the intravenous route at the indicated dose per mouse. For S. aureus, mice were infected by the intranasal route.
Mice, bacteria, and virus
Cluster assay
For quantification of bacteria, organs were homogenized and titrated on brain heart agar plate. For in vitro studies, cells were incubated with L.m. for 1 hour at 37°C, 5% CO 2 , and cells were then treated with gentamicin (10 g/ml) to kill extracellular bacteria. After 5 hours, cells were washed and lysed with distilled water + 1% Triton X-100 (Sigma, MO, USA) and titrated on brain heart agar plate.
Antibody and poly I:C treatment
Mice were treated intraperitoneally with 1 mg of anti-IFN-R-1 clone MAR1-5A3 (Leinco, MO, USA), isotype immunoglobulin 1 (Leinco), 500 or 50 g of anti-TNF- clone XT3.11 (Bio X Cell, NH, USA) (42), or 250 g of anti-IFN- clone XMG1.2 (Bio X Cell) (43) . Mice were injected with 200 g of poly I:C (Tocris, Bristol, UK).
Generation of bone marrow-derived DCs and transfer experiments
Primary DCs were generated by isolating bone marrow from femurs and tibias of mice and eliminating erythrocytes. DCs were generated by culturing bone marrow cells in very low endotoxin-Dulbecco's modified Eagle's medium (VLE-DMEM; Sigma, MO, USA) including 10% (v/v) fetal bovine serum (FBS; Thermo Fisher Scientific, MA, USA), 0.1% (v/v) -mercaptoethanol (-ME; Invitrogen, CA, USA), and granulocyte-macrophage colony-stimulating factor (GM-CSF; 10 ng/ml; made in house) (24) . Briefly, supernatant from X63-GM-CSF cell line was collected and titrated to obtain the best working concentration.
Eukaryotic cell lines
HeLa cells were purchased from ATCC-CCL2 and cultured in VLE-DMEM (Sigma) including 10% (v/v) FBS (Thermo Fisher Scientific) and 0.1% (v/v) -ME (Invitrogen).
Fluorescence-activated cell sorting
Spleens were digested with collagenase from Clostridium histolyticum type IV (Sigma), deoxyribonuclease I from bovine pancreas grade II (Roche, IN, USA), and trypsin inhibitor type II-S soybean. Cells were washed with phosphate-buffered saline (Thermo Fisher Scientific) and stained with anti-CD11c (clone N418; BioLegend, CA, USA), anti-CD11b (clone M1/70; BioLegend), anti-CD8a (clone 53-6.7; BioLegend), anti-Ly6G (clone RB6-8C5; BioLegend), and anti-Ly6C (clone HK1.4; BioLegend). For measuring intracellular proteins, anti-phospho-NF-B p65 (Ser 536 ; clone 93H1; Cell Signaling, MA, USA) was used. For ROS measurement, cells were incubated with dihydrorhodamine 123 (100 M; AnaSpec, CA, USA) for 30 min at 37°C.
Total RNA extraction, complementary DNA synthesis, and quantitative real-time polymerase chain reaction RNA was isolated from splenocytes or sorted cells with TRIzol (Thermo Fisher Scientific), as described by the manufacturer's protocol. The RNA was reverse-transcribed into complementary DNA with the QuantiTect Reverse Transcription Kit (Qiagen, Germany). Gene expression analysis was performed with assays from Qiagen: glyceraldehyde-3-phosphate dehydrogenase (GAPDH, QT01658692), 
Enzyme-linked immunosorbent assay
Multiplex enzyme-linked immunosorbent assay (ELISA) (Millipore, CA, USA) was performed to detect TNF- and IFN- in serum samples.
Transfection and USP18 overexpression pEBG-hUBP43 was a gift from D.-E. Zhang (Addgene, plasmid 12455) (28) . The plasmid was used in conjunction with the polymerase chain reaction (PCR)-based GeneArt Site-Directed Mutagenesis System (Life Technologies, Carlsbad, CA) to create USP18 C64A mutant plasmid. The primers used to construct the mutant were 5′-CAACATTGGACAGACCGCCTGCCTTAACTCCTTG-3′ and 5′-CAAGGAGTTAAGGCAGGCGGTCTGTCCAATGTTG-3′. Successful recombinants were selected on LB plates containing ampicillin. Plates were kept overnight at 37°C, and colonies were picked, cultured, and purified for sequencing (Eton Bio, San Diego, CA) to check for the desired substitution of cysteine residue 61 to alanine. L365F mutant of USP18 is cloned into pCMV3-FLAG vector. pWZL Neo Myr Flag MAP3K7 (TAK1) was a gift from W. Hahn and J. Zhao (Addgene, plasmid 20520). NEMO is cloned into pCAG vector. HeLa cells were transfected with 4 g of plasmid or empty vector using Lipofectamine 3000 (Invitrogen) for 24 hours. Cells were treated with human TNF- for 15 min. To generate THP-1 cells that overexpress USP18, THP-1 cells were infected with MIP-USP18 retrovirus and selected by puromycin.
Immunoprecipitation
Cells were lysed in binding buffer containing 25 mM tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, and 0.5% NP-40 for coimmunoprecipitation assays. The cell lysates were centrifuged (15,000 rpm) at 4°C for 5 min. All lysis buffers in this study contain proteinase and phosphatase inhibitors (Roche). Soluble fractions were precleared by protein G-Sepharose at 4°C for 15 min. Precleared cell lysates were immunoprecipitated for 1 hour with the anti-FLAG M2 agarose (Sigma). After three washes, immunocomplexes were eluted by boiling for 5 min.
Statistics
Data are expressed as means ± SD. Unpaired two-tailed Student's t test was calculated using GraphPad Prism to detect statistically significant differences between groups. Significant differences between several groups were detected by two-way analysis of variance (ANOVA). Log-rank (Mantel-Cox) test was used for survival study. The level of statistical significance was set at n.s. (not significant), *P < 0.05, **P < 0.01, ***P < 0.001, or ****P < 0.0001.
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